{"id":"NCT01026194","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes","officialTitle":"A Phase III Study of MP-513 in Combination With Thiazolidinedione in Japanese Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-12","primaryCompletion":"2011-06","completion":"2011-06","firstPosted":"2009-12-04","resultsPosted":"2013-10-28","lastUpdate":"2014-01-16"},"enrollment":204,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Placebo / Teneli (Teneligliptin) + pio (pioglitazone)","otherNames":[]},{"type":"DRUG","name":"Teneli / Teneli + pio","otherNames":[]}],"arms":[{"label":"Placebo / Teneli + Pio","type":"PLACEBO_COMPARATOR"},{"label":"Teneli / Teneli + pio","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of MP-513 (Teneligliptin) in combination with thiazolidinedione (pioglitazone) in patients with type 2 Diabetes for 12 weeks administration and to evaluate the safety and efficacy of MP-513 in combination with thiazolidinedione with an extension treatment for up to 52 weeks.","primaryOutcome":{"measure":"Change From Baseline in HbA1c at Week 12","timeFrame":"at Week 0 and Week 12","effectByArm":[{"arm":"Placebo/Teneli + Pio","deltaMin":-0.2,"sd":0.05},{"arm":"Teneli/Teneli + Pio","deltaMin":-0.94,"sd":0.04}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["24843712","24205974"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":101},"commonTop":["Nasopharyngitis","Upper respiratory tract inflammation","Glucose urine present","Blood urine present","Blood creatine phosphokinase increased"]}}